The effect of fenofibrate on the prevention of neonatal hyperbilirubinemia in mothers with O type blood group
Phase 3
Recruiting
- Conditions
- eonatal jaundice.Neonatal jaundice due to other excessive hemolysis
- Registration Number
- IRCT20200822048473N1
- Lead Sponsor
- Babol University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Term neonatal (37 weeks to 41 weeks and 6 days)
Neonatal with blood type A or B from mothers with positive O blood type and fathers with A, B or AB blood types
Without congenital anomalies, birth trauma and history of resuscitation at birth
Neonatal born by elective cesarean section who did not receive induction before delivery
Rh incompatibility
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Transcutaneous bilirubin level. Timepoint: Measurement of transcutaneous bilirubin levels at the end of 12, 24, 48 and 72 hours after birth and at the time of admission, in both control and fenofibrate groups. Method of measurement: Transcutaneous bilirubin meter.
- Secondary Outcome Measures
Name Time Method Jaundice leading to hospitalization. Timepoint: During hospitalization. Method of measurement: Blood test.;Duration of phototherapy. Timepoint: During hospitalization. Method of measurement: Duration in days.;The rate of severe jaundice. Timepoint: During hospitalization. Method of measurement: Blood test.